TrialScope, a Jersey City-based transparency and disclosure compliance solutions provider, announced Thursday it has acquired Clinical Trial Connect, a platform that connects patients to relevant clinical trials.
As part of the deal, Clinical Trial Connect’s algorithm will be used by TrialScope to enhance its platform.
“The acquisition of Clinical Trial Connect further strengthens TrialScope’s commitment to clinical trial disclosure, data sharing and patient engagement,” TrialScope CEO Jeff Kozloff said. “Mike Wenger has built an impressive technology platform that numerous advocacy groups deploy to help their members quickly and accurately match to relevant clinical trial options. This adds fuel to our innovation engine as we work to shift perception of transparency from a regulatory requirement to a strategic advantage.”
The combination of the two companies will help close the gap on some of the industry’s biggest challenges, such as structruing complex clinical trial data, trial data accuracy and availability and improved trial matching.
“TrialScope processes a jaw-dropping amount of data that is posted to ClinicalTrials.gov, over 40% of all industry studies,” Mike Wenger, founder of Clinical Trials Connect, said. “This reach, coupled with a customer roster of more than 25 of the world’s largest pharmaceutical sponsors, makes TrialScope the perfect home for Clinical Trial Connect’s technology. Together, we’ll reach and serve more life sciences companies, patients and families with tools to accelerate clinical trial searching and recruiting.”